<DOC>
	<DOCNO>NCT01294826</DOCNO>
	<brief_summary>The study determine maximum tolerate dose ( MTD ) AUY922 give combination cetuximab previously treat patient KRAS wild-type metastatic colorectal cancer .</brief_summary>
	<brief_title>Study AUY922 Cetuximab Patients With KRAS Wild-Type Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically cytologically confirm colorectal cancer KRAS wild type metastatic colorectal cancer Progression disease least 2 prior therapy include 5FU , oxaliplatin bevacizumab irinotecan Prior treatment cetuximab allow ( full dose tolerate ) , provide patient never require dose reduction due toxicity Must least one measurable lesion Must 18 year age old ECOG performance status 01 Life expectancy must great 12 week For woman childbearing potential , negative pregnancy blood test must obtain less 3 day prior first AUY922 infusion Colorectal cancer KRAS mutation KRAS genotype status unknown Metastasis CNS Prior treatment Hsp90 inhibitor compound Patients received systemic anticancer treatment prior first dose AUY922 within follow time frame : Radiotherapy , conventional chemotherapy : within 2 week Palliative radiotherapy : within 2 week Nitrosoureas , monoclonal antibody , trastuzumab mitomycin : within 6 week Any continuousdosing ( i.e . daily dosing , everyotherday dosing , MondayWednesdayFriday dosing , weekly etc . ) systemic anticancer treatment recover period know , investigational drug ( i.e . targeted agent ) within duration ≤ 5 half life agent active metabolite ( ) Treatment therapeutic dos coumadintype anticoagulant . [ Maximum daily dose 2mg , line patency permit ] Known sensitivity cetuximab Unresolved ≥ grade 1 diarrhea Malignant ascites require invasive treatment Concurrent medication substrate , inhibitor inducer CYP3A4 , CYP2C8 , CYP2C9 CYP2C19 switch discontinue switched alternative drug prior commence AUY922 dose need special consideration case case basis Major surgery ≤ 2 week prior randomization recover therapy Impaired cardiac function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Colorectal Neoplasms</keyword>
	<keyword>Intestinal Neoplasms</keyword>
	<keyword>Gastrointestinal Neoplasms</keyword>
	<keyword>Digestive System Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Colonic Diseases</keyword>
	<keyword>Intestinal Diseases</keyword>
	<keyword>Rectal Diseases</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>HSP90 Heat-Shock Proteins</keyword>
	<keyword>EGFR protein , human</keyword>
</DOC>